Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.41 USD | +3.87% | +2.97% | -2.42% |
May. 28 | Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday | MT |
May. 28 | Agios Pharmaceuticals to Sell 15% Vorasidenib Royalty Rights to Royalty Pharma for $905 Million | MT |
Financials (USD)
Sales 2024 * | 2.65B | Sales 2025 * | 2.92B | Capitalization | 12.36B |
---|---|---|---|---|---|
Net income 2024 * | 942M | Net income 2025 * | 1.1B | EV / Sales 2024 * | 6.84 x |
Net Debt 2024 * | 5.78B | Net Debt 2025 * | 6.04B | EV / Sales 2025 * | 6.3 x |
P/E ratio 2024 * |
13
x | P/E ratio 2025 * |
11.1
x | Employees | - |
Yield 2024 * |
3.29% | Yield 2025 * |
3.56% | Free-Float | 85.52% |
Latest transcript on Royalty Pharma plc
1 day | +3.87% | ||
1 week | +2.97% | ||
1 month | -1.05% | ||
3 months | -9.66% | ||
6 months | +1.26% | ||
Current year | -2.42% |
Managers | Title | Age | Since |
---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 60 | 95-12-31 |
Terrance Coyne
DFI | Director of Finance/CFO | 42 | 09-12-31 |
Arthur McGivern
CIO | Chief Investment Officer | - | 22-10-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
FOU | Founder | 71 | 95-12-31 |
Errol de Souza
BRD | Director/Board Member | 70 | 20-05-31 |
David Hodgson
BRD | Director/Board Member | 67 | 22-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.98% | 254 M€ | +13.69% | - | |
0.51% | 5 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 27.41 | +3.87% | 7,227,040 |
24-05-30 | 26.39 | -.--% | 4,424,355 |
24-05-29 | 26.39 | -0.94% | 3,171,652 |
24-05-28 | 26.64 | +0.08% | 3,118,081 |
24-05-24 | 26.62 | -0.86% | 1,727,314 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.42% | 12.36B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- RPRX Stock